Transcription
Last fall, we covered the White House press conference that started all of this, then the CMS announcement, then the bridge details. This is our fourth video on Medicare GLP-1 coverage, and it is the first one where we can tell you that the path to 2027 is finally starting to make sense. So, let's talk about what that means for you.
If you're new to this story, we're going to walk you through everything from the beginning, how the bridge works, who qualifies, what it costs, and what you need to do before open enrollment this fall. You will have the full picture by the end of this video.
If you've been watching us cover this since the beginning, there are some important updates directly from the Centers for Medicare and Medicaid Services, or CMS FAQ, that we want to make sure you hear. If you'd like to read the FAQs yourself, I'll leave a link in the description.
The FAQs include the answer to one of the most common questions we have been getting, which is what happens if you've already lost weight and your BMI is now below the threshold. CMS has addressed that directly, and the answer is going to matter to a lot of people watching this.
We also have the confirmation that the BALANCE model is launching in Medicare in January 2027. The 80% plan participation threshold has been met. That was the last major open question, and it is now answered.
Welcome to the Downsized. I'm Christopher Durham, and along with my wife, Lorraine, we have lost more than 150 lb using GLP-1s, and we've been documenting this whole experience right here on YouTube. We're not doctors, and this is not medical advice, but we've spent the last couple of years talking to patients and providers and following this space very closely. Our job is to translate what is happening into something that makes sense for you and I, for the patients who are actually living it.
If you're new here, we cover GLP-1 medications, obesity treatment access, and pricing constantly. We do patient interviews, we do doctor interviews. Occasionally, I cook. We do live streams every week on Wednesday nights if you have questions. So, if all of that is useful to you, please take a second to like and subscribe. It really does help more people find us.
Before we get into the details, I want to address something directly. A lot of people watching this are not on Medicare. Maybe you're in your 40s. Maybe you're commercially insured. Maybe you are already on a GLP-1 and you are paying out of pocket or fighting your employer plan for coverage. And when you hear a Medicare story, your instinct is to move on because it doesn't feel like your problem.
Stay with me on this one, though, because this story is actually about you, too. Medicare coverage decisions are one of the most powerful signals in the entire American healthcare system. When Medicare begins covering something and the data supports it, commercial insurers follow. Not immediately and not automatically, but the pattern over decades is consistent. The eligibility criteria Medicare establishes, the clinical framework it builds, the pricing benchmarks it negotiates, all of that become the foundation that commercial payers look at when they make their own decisions.
Right now, a significant number of insurance plans still do not cover GLP-1s for obesity. The landscape has been improving, but there are people watching this video who are on a commercial plan and still either paying full price out of pocket or being denied outright. Or like Lorraine and I, who do not have access to buy a commercial plan at any price. So, we're a small business, we work through the marketplace, there are no plans available to us. We've been paying cash all along. Ultimately, the goal would be to get insurance to cover this, not to have to pay cash.
The access problem, though, is not unique to Medicare patients. If these demonstration programs succeed, if the data shows that covering these medications reduces hospitalizations, lowers cardiovascular events, and produces long-term savings, that shifts the argument entirely. It moves from this is expensive to not covering this is more expensive. And that is the argument that changes coverage decisions at scale.
So, if you're in your 40s, paying out of pocket right now, or appealing a denial, or waiting for your employer to add obesity coverage, this is the proof of concept that could change how the entire insurance system treats obesity as the chronic disease it is. We're not there yet, and it may take a while, but that is what is at stake, and that is why this matters to everyone, not just the people who are on Medicare today.
Now, let's get into exactly what is happening. Before we get into what is changing, though, let me be honest about where things stand right now. Medicare today still does not cover GLP-1 medications when they are prescribed specifically to treat obesity. There are situations where Medicare covers these drugs, but it depends on what condition is being treated. Type 2 diabetes, yes. Cardiovascular risk reduction in certain patients, yes. Sleep apnea, yes. But obesity alone as the diagnosis, that is still where the wall is.
And on top of that, Medicare patients cannot use manufacturer savings cards. So, the same medication that an insured patient might be getting at a significant discount is costing someone on Medicare potentially over $1,000 a month out of pocket. Now, I know that sounds crazy, but today, if you're using, for instance, a Novo Nordisk medication, well, the only way to get those discounted prices is with a savings card. You cannot use a savings card if you're using Medicare. We hear about this constantly. Someone finds something that finally works for them, and then [laughter] they hit Medicare, and the financial pathway disappears. And that's the reality right now. That's why many people have gone to compound it.
So, here is what is actually being introduced. This is a lot. This is a long video. There's a lot of detail here. This is not Medicare flipping a switch and covering these medications across the board. What has been put in place is a structured, phased rollout of two separate programs designed to test how GLP-1s get introduced into the Medicare system over time. Two programs, different timelines, different mechanics, and neither one is a guarantee for everyone.
The first is a short-term demonstration program that CMS is calling the Medicare GLP-1 bridge, and it starts July 1st, 2026. The second is a longer-term program called the BALANCE model, which is set to begin in 2027 and run through 2031. Most of the headlines that are talking about that $50 price are referring to the bridge when they say Medicare is covering GLP-1s in 2026. But the bridge is only 6 months long, and what happens after it depends on a whole other set of decisions. So, let's talk through both.
We'll start with the Medicare GLP-1 bridge program. The bridge runs from July 1st, 2026 through December 31st, 2026. 6 months. As of right now, there's nothing you or your doctor can do until it opens. And one of the most important things to understand right away is that it does not run through your normal Medicare Part D plan. This is not your plan making a coverage decision. CMS is stepping in and running this directly as a nationwide program. That means your Part D plan does not need to opt in for you to have access. It means the plan you happen to be enrolled in does not determine whether you qualify, and it means this is available in every state and territory, not just certain ones.
Behind the scenes, CMS is using a single central processor to manage everything. Prior authorizations go through it, claims go through it, pharmacy payments go through it. And CMS has now named that processor. It is Humana. Now, I want to be clear about what that means because this has been described in many ways that make it sound like some neutral federal system. Humana is not a government agency. It is a for-profit health insurance company, one of the largest in the country. CMS has contracted with Humana to run this program using infrastructure Humana already operates for the LI Net program, which provides transition drug coverage for low-income Medicare beneficiaries. CMS chose this approach because that infrastructure already exists at national scale and can be operational by July 1st. They are not building something from scratch. Whether you find that reassuring or complicated probably depends on your own experience with the insurance industry and Humana and the LI Net program. What it means practically is that the entity processing your prior authorization and handling your pharmacy claim is Humana. Under contract to CMS, not a federal agency doing it directly. Your Part D plan is essentially on the sideline for these 6 months. CMS and Humana are running the operation directly. That structure removes one of the biggest variables that usually creates access problems in Medicare, which is whether your specific plan has decided to cover something. For the bridge, that question does not apply.
So, how do you actually get access? You cannot sign up online, you cannot walk into a pharmacy and ask for it. The process starts with your provider. Your doctor writes the prescription and submits a prior authorization request directly to the central processor, which is Humana, not to your Part D plan. That's a critical distinction, and CMS has said they will be doing outreach and education to help providers understand the difference. Because if a provider accidentally routes a prior authorization request for an obesity prescription to a patient's Part D plan instead of to the central processor, that request is going to the wrong place and it will be denied. To be specific about when each pathway applies, if a GLP-1 is being prescribed specifically for obesity and weight reduction, that goes through the bridge and the prior authorization goes to Humana. If the same medication is being prescribed for a different reason that is already covered under Part D like Zepbound for sleep apnea or Wegovy for cardiovascular risk reduction, that stays in the Part D plan entirely. The bridge does not apply in those situations. Your provider needs to understand which pathway applies to your specific prescription.
You do not need to be enrolled in Medicare with prescription drug coverage, either a standalone Part D plan or a Medicare Advantage plan that includes drug coverage. One practical note on how this works at the pharmacy. Claims have to be submitted electronically using a specific standard. Paper claims are not accepted. Direct reimbursements to members are not accepted. Everything runs through the electronic system, which means your provider and your pharmacy both need to be set up correctly before your prescription is filled. Now, this is pretty common systems. There is nothing that your doctor doesn't use every day. So, I wouldn't get worried about it.
Now, let's talk about who qualifies. Because the criteria are specific. And this is the part where a lot of people are going to find out whether they are in or not. CMS has published three eligibility tiers. You need to meet one of them.
So, tier number one, if your BMI was 35 or higher at the time you started GLP-1 therapy, that alone qualifies you. No additional conditions required.
If your BMI was 30 or higher, you also need a qualifying related condition. Specifically, heart failure with preserved ejection fraction, chronic kidney disease at stage 3A or above, or uncontrolled hypertension. And on that last one, CMS gives a precise clinical definition. It is not just high blood pressure. It means your blood pressure is above 140 over 90 despite being on two antihypertensive medications at the same time. That's the bar. If your blood pressure is managed on medication, that is not the same thing. Talk to your provider about where you actually stand.
And if your BMI was 27 or higher, you need a more significant cardiovascular or metabolic history, prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease. On prediabetes specifically, CMS defines it according to American Diabetes Association guidelines. If you have been told your blood sugar is elevated, but you are not sure whether it officially meets that threshold, that is a conversation to have with your provider before July. The label matters here. Please don't make any assumptions here. Talk to your doctor.
In all cases, the medication has to be prescribed specifically to reduce body weight and maintain weight loss, and it has to be used alongside ongoing lifestyle changes, including structured nutrition and physical activity consistent with the FDA-approved labeling.
Now, here's the piece I really want people to hear because this question has been coming up constantly in our comments. Eligibility is based on your BMI when you started GLP-1 therapy, not where you are today. You can breathe a sigh of relief. I know thousands of you have asked me that question. So, if you started on Zepbound or Wegovy with a BMI of 37 and you are now down to 34, you still qualify. CMS spells this out explicitly. They give that exact example. You are not being penalized for the progress you've already made.
CMS is explicit that this applies even if you started GLP-1 therapy before you were ever enrolled in Medicare Part D. So, if you were on commercial insurance, started GLP-1s two or three years ago, lost 50 lb, and then transitioned on to Medicare, you do not lose eligibility because of that transition. What your provider needs to document is your BMI at the time you first initiated therapy, wherever you were insured at the time. That changes the math for a lot of people who assume they missed the window. They did not. The question is always the same. What was your BMI when you started? That is what CMS wants to know.
And one more thing on this. The initiation of GLP-1 therapy does not have to mean one of the brand name medications covered under the bridge. If you started on any GLP-1, including a compounded version, and your BMI at that time met one of these three tiers, that history counts. Your provider needs to document your starting point. That is the number that matters to CMS, not what you are taking right now or what you were taking at the time. For people who are already on treatment, this means eligibility is largely a documentation question. Can your provider attest to what your BMI was when you initiated GLP-1s? Can they document your medical history at that time? That is what needs to be in place before July.
And on the provider question, telehealth is not excluded. CMS is not requiring you to be seeing an in-person physician. What matters is that you have a licensed provider who can accurately document your history and submit the prior authorization to the correct processor. The origin of your care does not disqualify you.
Now, let's talk about the medications themselves. The medications covered under the bridge are Wegovy in both injection and tablet form, Foundaeo, which is the oral GLP-1 that received FDA approval earlier this year, and Zepbound, but only the QuickPen. That last part is important. CMS updated its guidance in April of 2026 to clarify that only the QuickPen version of Zepbound is included in the bridge. The single-dose vial and the single-dose pen formulation single-dose vial and the single-dose pen formulations are not. So, this is not just about being on the right medication. It is about being on the right version of it. Your provider and your pharmacy both need to make sure the prescription matches exactly what CMS has approved.
And to be clear on Ozempic and Mounjaro, those medications are not covered under the bridge for weight loss. They may be covered through your regular Part D plan if they are prescribed for type 2 diabetes, but the bridge is specifically for the FDA-approved weight loss formulations.
Now, let's talk about cost. I don't want to be precise here because the $50 number is real, but there are details most of the coverage is leaving out. CMS has negotiated the price of these medications down to $245 a month under the bridge. What that means is that's what CMS pays. The patient pays $50. CMS covers the rest. And that is the federal government using its negotiating leverage to get a price point that the commercial market has not produced at scale for Medicare patients. And compared to someone paying over $1,000 a month or even 499 with coupons, that is a real significant difference.
But here's what most headlines are not telling you. That $50 does not count toward your Part D out-of-pocket spending cap. Medicare Part D has an annual out-of-pocket threshold of $2,100 in 2026, and spending under the bridge does not accumulate towards it. So, if you're managing multiple prescriptions and tracking your cost towards that cap, your GLP-1 copays under the bridge program are sitting in a separate bucket entirely. It is $50 flat every month outside the normal Part D structure. That's still dramatically better than what most people are paying today, but it is an important nuance to understand, especially if you're budgeting carefully or relying on hitting that out-of-pocket cap for relief on other medications.
Also worth knowing, the bridge is the primary payer for these claims and does not coordinate benefits with other insurance. Coupons and discount programs cannot be applied to bridge claims. There is no way to layer other coverage or savings programs on top of it.
And then there's this. The bridge ends December 31st, 2026. Getting access through the bridge does not mean you stay on. To maintain coverage in 2027, you need to be enrolled in a Medicare Part D plan that is participating in the Balance Model. That transition is not automatic. Nobody's going to move you. It requires a deliberate decision during open enrollment this fall. CMS has said they will be doing beneficiary outreach and education about this transition in the months ahead, but do not wait for a letter. Start thinking about it now.
So, the bridge is the first step. It is not the final system. When you step back and look at all of this, what CMS is doing is deliberate. They're opening access to a defined group of patients at a controlled cost in a way they can measure at a national level. But it's structured. It's limited. And it depends entirely on eligibility and provider involvement. This is real progress, but it is not open access and is not guaranteed for everyone.
So, now let's talk about the Balance Model. So, what actually happens after 2026? Balance is the longer-term program, and it works very differently from bridge. Instead of CMS running everything centrally the way it does in 2026, they step into a different role. They negotiate pricing and coverage terms with drug manufacturers, and then individual Medicare Part D plans and state Medicaid programs decide whether they want to participate.
CMS describes it as voluntary, and that single word shapes everything about how this is going to work in the real world. Voluntary means no plan is required to offer it. Plans have to go through a formal application process with CMS to participate, and you should expect real variation. Some plans will offer it, some will not. Starting in January 2027, whether you have access to these medications through Medicare will depend entirely on which plan you're enrolled in. This is a fundamental shift from 2026, where your plan is irrelevant because CMS is running everything directly.
Now, here is something we can tell you for the first time in this video, and it matters a great deal. CMS required that at least 80% of Medicare Part D plans sign on to balance for the model to launch in Medicare in 2027. That threshold existed because if not enough plans participated, the whole Medicare side of the model simply would not launch. And people who got coverage through their bridge in 2026 could have lost access entirely come January 1st. This week CMS confirms that that threshold has been met. Balance will launch in Medicare in January 2027. That's confirmed. Which means the question for you is no longer whether this happens. It is whether your specific plan is one of the participating ones. And that is what open enrollment this fall is going to determine for a lot of people watching this video.
Balance also runs in parallel through Medicaid. States can begin joining the model as early as May 2026. So, that side of things is already moving. Depending on whether someone is on Medicare or Medicaid, and depending on where they live, and which plan they are enrolled in, access is going to look different across the country.
In terms of who qualifies under balance, the framework follows similar logic to the bridge. CMS is anchoring eligibility around BMI or related health conditions, and still requiring ongoing lifestyle support alongside this medication. Now, we're not sure how that takes shape. More to come. But the model is framed around metabolic health and long-term disease prevention more broadly. Conditions like cardiovascular disease, kidney disease, and sleep apnea are all part of the picture.
The medication list under balance expands significantly beyond what the bridge covers. All formulations of Mounjaro, Ozempic, Rybelsus, and Wegovy are included, along with the QuickPen formulation of Zepbound and/or Forxiga Pron, or as we now know it, Foundeo. CMS has been clear that this list can grow over time as new therapies are approved. That is meaningful because it means people who are currently on Mounjaro or Ozempic for weight management may have a coverage pathway under balance that does not exist under the bridge.
On cost under balance, there's no single number to give you. On cost under balance, there's no single number to give you the way there is for the bridge. CMS has negotiated that similar $245 net price that they will pay to the manufacturers as the foundation for 2027. The same price point as bridge, but what individual patients actually pay will depend on their specific plan and how that plan structures cost sharing. CMS has said it may establish out-of-pocket limits, but the details of what that looks like plan by plan are still coming.
And I want to be direct about something. Coverage is not guaranteed for every individual. You still have to meet the clinical eligibility criteria. Your plan still has to be one of the participating ones, and you have to make the right enrollment decision this fall. There are still multiple steps between today and having a covered prescription in your hand in 2027.
There's also something bigger worth understanding about what balance actually is and is not. The underlying law that prevents Medicare from covering medications prescribed specifically for weight loss has not been changed. Medicare is still statutorily prohibited from doing that. What CMS is doing with bridge and with balance is running demonstration programs under existing federal authority. They are testing whether broader access produces better health outcomes and lower long-term health costs. A permanent fix to that statute would require an act of Congress. The Treat and Reduce Obesity Act has been introduced in various forms for years and has not passed. Until it does, or something similar, everything CMS is doing here operates under demonstration authority and not permanent law. These programs could end. They could be modified. A future administration could make different decisions. That's the honest context.
So, I said this at the top, and I want to come back to it here because it deserves more than a passing mention. If you're on commercial insurance, your regular insurance your employer takes care of for you, you have a copay, everything that most people have, and you're still fighting for GLP-1 coverage, what happens with these Medicare programs directly impacts your situation. Not immediately, not automatically, but here is how it works.
Medicare coverage decisions have historically been one of the most powerful signals in the insurance market. When Medicare establishes clinical eligibility criteria, negotiates a price point, and generates real-world data on outcomes and cost savings, commercial payers use that as a roadmap. The argument that covering these medications is too expensive becomes much harder to make when the federal government has a 5-year data set showing it reduces hospitalizations, heart attacks, and long-term costs.
Right now, the fight for your insurance coverage of GLP-1s for obesity is still being had plan by plan, employer by employer. If balance produces the outcomes CMS is hoping for, you and I are hoping for, that fight gets easier. Not just for Medicare patients, but for everyone. So, watch what happens here. The open enrollment decisions Medicare patients make this fall, the utilization data that comes out of the bridge in 2026, and the outcomes data that starts accumulating under balance in 2027 and beyond. All of that is going to shape the commercial coverage landscape for people who are nowhere near Medicare age.
So, the question is really what do you do right now? If you're on Medicare and thinking about the bridge, the answer starts with two specific conversations with your provider before July 1st.
First, is your starting BMI documented in your chart? Not where you are today, where you were when you first initiated GLP-1s. And remember that includes any GLP-1 you may have started on even a compounded version, and even if you were on commercial insurance at the time. That starting BMI is the number CMS cares about.
Second, is your doctor set up to submit prior authorization requests through the CMS bridge system when it opens in July? They're using Humana's program, so they should be, but ask. Specifically, do they understand that obesity prescriptions go to the central processor, which is Humana, and not your Part D plan? Not every provider is going to move quickly on this, and routing errors in the early weeks of the program are real risk. Make sure yours knows how this works before July 1st.
I'll leave a link to the CMS FAQs in this description. When everything opens on July 1st, they will update those and give your doctor and you the information you need. Those two questions will tell you whether you're ready to go in July, or whether there is groundwork to lay first.
If you're thinking about 2027 and beyond, your focus needs to shift to your plan during open enrollment this fall. Balance is launching. That's now confirmed, but not every plan is participating. Most of them, it looks like, will. But you do need to make sure that yours is. The most important question you can ask any plan you're considering is whether they are participating in the balance model. Ask it directly. Don't be afraid of it. Get a clear answer. The plan you choose this fall could determine whether you maintain access after December 31st, or face a gap in coverage at the start of 2027.
CMS has said that they will be doing beneficiary outreach about the bridge to balance transition. But the history of Medicare transitions is that people who plan ahead do better than people who wait for a letter. Do not wait for a letter.
So, when you step back and look at the full picture, you can see exactly why there's so much confusion right now. Two kind of complicated programs that aren't going to work together, but hopefully open access. People are hearing that Medicare is going to cover GLP-1 medications for obesity, and in a meaningful sense, that is indeed true. But it's not happening all at once, and it is not as simple as a single policy change.
In 2026, CMS is testing access directly through bridge, 6-months nationwide program, Humana processing the claims under CMS contract, patients paying $50 a month. In 2027, balance launches in Medicare. That is now confirmed as of this week. And from that point forward, what you have access to depends on your eligibility, your provider, and the plan you choose during open enrollment. That's the reality.
And for a lot of people, this is genuinely a significant moment. Not just for Medicare patients, but for everyone who's been fighting to have obesity treated as a chronic disease, as the chronic disease it is, we celebrate anyone at any age, anywhere in the world getting affordable access to the health care, the GLP-1s they need. Because if this works, it does not stay contained in Medicare, it becomes the foundation that the rest of the system builds on.
We've been covering this since the beginning and we're going to keep covering it. This is our fourth video on this and it will not be the last, so stay tuned. There's more to come as more rolls out. If this video helped clarify things for you, please hit like right now. It genuinely helps more people find us who are trying to figure this out. And if you haven't already subscribed, if you want to stay on top of everything that is happening with GLP-1s access and pricing, or follow along with Lorraine and I on our journey, we are following in real time.
I want to hear from you in the comments. Are you on Medicare today or getting close? Are you on commercial insurance and still fighting for coverage? After hearing all of this, what is your biggest remaining question? Drop it below. Those conversations shape exactly what we discuss next. Make sure to join us on Wednesday night at 7:00 Eastern Standard Time, where we'll take your questions live right here on YouTube. My name is Christopher Durham and we are The Downsized.